Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]).

@article{Beran2011LevetiracetamIC,
  title={Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]).},
  author={Roy G Beran and Paul J Spira},
  journal={Cephalalgia : an international journal of headache},
  year={2011},
  volume={31 5},
  pages={530-6}
}
INTRODUCTION Chronic daily headache (CDH) represents a temporal profile of headache (15+ days/month; 4+ hours/day; >6 months). We report the first comprehensive and largest levetiracetam (LEV) trial in CDH. METHODS A 27-week, multi-centre, randomised, placebo-controlled, cross-over, phase III B study assessed efficacy of a target of 3 g/day LEV of 6 placebo tablets/day in CDH. Primary efficacy was headache-free rate (HFR) while secondary parameters were loss of diagnostic criteria; severity… CONTINUE READING

From This Paper

Topics from this paper.
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…